Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction

2006 ◽  
Vol 112 (1) ◽  
pp. 52-58 ◽  
Author(s):  
Yoshitaka Ohashi ◽  
Seinosuke Kawashima ◽  
Takao Mori ◽  
Mitsuyasu Terashima ◽  
Shinobu Ichikawa ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Interleukin 6 ◽  
Coronary Circulation ◽  
Cd40 Ligand ◽  
Soluble Cd40 Ligand

scholarly journals Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study

2010 ◽  
Vol 26 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Mehmet Kayrak ◽  
Ahmet Bacaksiz ◽  
Mehmet S. Ulgen ◽  
Mehmet Akif Vatankulu ◽  
Kadriye Zengin ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Pilot Study ◽  
Plasma Concentrations ◽  
Cd40 Ligand ◽  
Soluble Cd40 Ligand

Detecting plaque rupture? Soluble CD40 ligand for early diagnosis of acute myocardial infarction in the emergency department

2010 ◽  
Vol 27 (Suppl 1) ◽  
pp. A6.2-A6
Author(s):  
Richard Body
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Emergency Department ◽  
Early Diagnosis ◽  
Adverse Events ◽  
Troponin T ◽  
Cd40 Ligand ◽  
Soluble Cd40 Ligand ◽  
Calcium Blockers ◽  
Significant Difference

BackgroundIn recent years there has been growing interest in the identification of novel biomarkers that may enable early exclusion of acute coronary syndromes (ACS) in the Emergency Department (ED). Soluble CD40 ligand (sCD40L) has been identified as a potential marker of coronary plaque destabilisation and platelet activation. We aimed to investigate the value of sCD40L measured at the time of ED presentation for enabling early diagnosis and exclusion of ACS.MethodsWe recruited patients presenting to the ED with suspected cardiac chest pain within the previous 24 h. We measured sCD40L in plasma samples taken at the point of ED presentation. All patients had troponin T measured at least 12 h after symptom onset and were followed up for 6 months for adverse events (death, acute myocardial infarction (AMI) or the need for urgent revascularisation).Results706 patients were recruited to the study. sCD40L levels were significantly lower in smokers, in patients with hyperlipidaemia or prior coronary revascularisation and in patients taking statins, r angiotensin-converting enzyme or calcium blockers. There was no significant difference in sCD40L levels between patients with (median 33.8ng/ml, IQR 18.0–80.5) and without (36.3 ng/ml, IQR 14.2–94.3) AMI (p=0.92) or between patients who did (34.0 ng/ml, 14.2–94.3) and who did not (34.9, 18.2–80.4) develop adverse events (p=0.82). The area under the Receiver Operating Characteristic curve was 0.50 (95% CI 0.45 to 0.56) for AMI and 0.49 (0.44–0.55) for adverse events. There was no trend towards increasing incidence of either outcome with ascending quintiles of sCD40L.ConclusionssCD40L is unhelpful in the ED diagnosis of ACS. Future work in this area should focus on other biomarkers.

scholarly journals Lack of Association of Soluble CD40 Ligand with the Presence of Acute Myocardial Infarction or Ischemic Stroke in the Emergency Department

2009 ◽  
Vol 55 (1) ◽  
pp. 175-178 ◽  
Author(s):  
Michaela Plaikner ◽  
Andreas Peer ◽  
Gerda Falkensammer ◽  
Christoph Schmidauer ◽  
Christoph Pechlaner ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Emergency Department ◽  
Ischemic Stroke ◽  
Diagnostic Marker ◽  
Linear Regression Analysis ◽  
Cd40 Ligand ◽  
Multiple Linear Regression Analysis ◽  
Soluble Cd40 Ligand ◽  
Reactive Protein

Abstract Background: Soluble CD40 ligand (sCD40L) has been proposed as a new risk marker for cardiovascular diseases; however, its possible role as a diagnostic marker in the emergency department (ED) has not yet been investigated. Methods: We investigated sCD40L for the diagnosis of acute myocardial infarction or ischemic stroke in 1089 consecutive patients (525 males, 564 females; age, 17–98 years; median, 56 years) in an ED treating mainly adults with medical or neurologic emergencies. We used a research assay from Roche Diagnostics to measure sCD40L in heparinized plasma prepared from routinely drawn blood samples. Results: Intraassay and interassay CVs in our laboratory ranged from 1.6%–4.2% and from 4.4%–4.9%, respectively. A multiple linear regression analysis revealed sCD40L concentration to be significantly associated with C-reactive protein concentration (P = 0.012) and platelet count (P < 0.001). In addition, a subgroup analysis revealed a significant association between smoking and sCD40L concentration (P = 0.006). All other tested variables, including discharge diagnosis, age, sex, and other laboratory variables, showed no significant associations. Conclusions: In adults presenting to the ED, sCD40L is not useful as a diagnostic marker for acute cardiac, cerebrovascular ischemic, or thromboembolic events.

Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction

2006 ◽  
Vol 118 (2) ◽  
pp. 189-197 ◽  
Author(s):  
Nicholas L.M. Cruden ◽  
Catriona Graham ◽  
Scott A. Harding ◽  
Christopher A. Ludlam ◽  
Keith A.A. Fox ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cd40 Ligand ◽  
Soluble Cd40 Ligand

scholarly journals Biomarkers of acute myocardial infarction: diagnostic and prognostic value. Part 1 (literature review)

2020 ◽  
Author(s):  
Aleksey Michailovich Chaulin ◽  
Dmitry Viktorovich Duplyakov
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Growth Factor ◽  
Prognostic Value ◽  
Cd40 Ligand ◽  
Cardiac Biomarkers ◽  
Economic Damage ◽  
Soluble Cd40 Ligand ◽  
Fatty Acid Binding ◽  
Diagnostic And Prognostic Value

Morbidity and mortality rates from acute myocardial infarction (AMI) have been growing rapidly in recent years, causing significant socio-economic damage. Cardiac biomarkers play an important role in the diagnosis and prediction of AMI. In our review article, we will summarize information about the main existing cardiac biomarkers and focus on their diagnostic and prognostic value for patients with AMI. In the first part of the review, we consider the diagnostic and prognostic value of biomarkers of necrosis and myocardial ischemia (aspartate aminotransferase; creatine phosphokinase; cardiac troponins; myoglobin, ischemia-modified albumin, fatty acid binding protein) and neuroendocrine AMI biomarkers (natriuretic peptides, adrenomedullin, catestatin, components of the renin-angiotensin-aldosterone system). In the second part of the review, we discuss the diagnostic and prognostic value of inflammatory AMI biomarkers (C-reactive protein, interleukin-6, tumor necrosis factor, myeloperoxidase, matrix metalloproteinases, soluble CD40 ligand form (sCD40L), procalcitonin, placental growth factor (PGF), procalcitonin) and recently discovered new biomarkers (microRNA, stimulating growth factor, expressed by genome 2 (ST2), growth differentiation factor 15 (GDF-15), galectin-3).

scholarly journals Interleukin-6 release predicts myocardial recovery (stunning) after acute myocardial infarction

1998 ◽  
Vol 31 ◽  
pp. 134
Author(s):  
W.K. Lagrand ◽  
F. Nijland ◽  
C.E. Hack ◽  
W.Th. Hermens ◽  
P.G.M. Jansen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Interleukin 6 ◽  
Myocardial Recovery
Sign in / Sign up

Export Citation Format

Share Document